Background: Continuing care following inpatient addiction treatment is an important component in the continuum of clinical services. Mutual help, including 12-step groups like Alcoholics Anonymous, is often recommended as a form of continuing care. However, the effectiveness of 12-step groups is difficult to establish using observational studies due to the risks of selection bias (or confounding).
Objective: To address this limitation, we used both conventional and machine learning-based propensity score (PS) methods to examine the effectiveness of 12-step group involvement following inpatient treatment on substance use over a 12-month period.
Methods: Using data from the Recovery Journey Project - a longitudinal, observational study - we followed an inpatient sample over 12-months post-treatment to assess the effect of 12-step involvement on substance use at 12-months (n = 254). Specifically, PS models were constructed based on 34 unbalanced confounders and four PS-based methods were applied: matching, inverse probability weighting (IPW), doubly robust (DR) with matching, and DR with IPW.
Results: Each PS-based method minimized the potential of confounding from unbalanced variables and demonstrated a significant effect (p < 0.001) between high 12-step involvement (i.e., defined as having a home group; having a sponsor; attending at least one meeting per week; and, being involved in service work) and a reduced likelihood of using substances over the 12-month period (odds ratios 0.11 to 0.32).
Conclusions: PS-based methods effectively reduced potential confounding influences and provided robust evidence of a significant effect. Nonetheless, results should be considered in light of the relatively high attrition rate, potentially limiting their generalizability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drugalcdep.2021.108943 | DOI Listing |
Clin Transl Allergy
October 2024
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey.
Background: Following the increased use of biological agents, a subset of patients experiences hypersensitivity reaction (HSR). We reported our experience with rapid drug desensitization (RDD) to nine biologics (rituximab, infliximab, cetuximab, trastuzumab, pertuzumab, nivolumab, brentuximab, tocilizumab and filgrastim) and identified risk factors for breakthrough reactions (BTRs).
Method: This was a retrospective review (2013-2022) of patients with immediate HSRs to biological agents.
J Subst Use Addict Treat
December 2024
The PRIDE Study/PRIDEnet, Stanford University School of Medicine, United States of America; Department of Community Health Systems, School of Nursing, University of California, San Francisco, United States of America; Alliance Health Project, Department of Psychiatry, School of Medicine, University of California, San Francisco, United States of America.
Introduction: Sexual minority (e.g., bisexual, gay, lesbian, queer) and gender minority (e.
View Article and Find Full Text PDFJ Oncol Pharm Pract
August 2024
Oncology Service, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr José Eleuterio González", Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
Introduction: Taxanes and platinum are first-line treatments in gynecological tumors with high rates of hypersensitivity reactions (HSRs), leading to discontinuation of treatment. Desensitization involves induction of temporary tolerance to previously sensitized medications. The aims of this study are to describe HSRs to paclitaxel and carboplatin and evaluate the safety and effectiveness of desensitization protocols in gynecological cancer patients.
View Article and Find Full Text PDFJ Addict Med
August 2024
From the David Geffen School of Medicine at UCLA, Los Angeles, CA (TA); Department of Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA (FV); UCLA Semel Institute, Los Angeles, CA (RM); Department of Psychiatry and Biobehavioral Science, UCLA, Los Angeles, CA (IM); and Department of Emergency Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA (EAS).
Front Psychiatry
June 2024
Tuscaloosa VA Medical Center, Tuscaloosa, AL, United States.
Introduction: Medications for opioid use disorders (MOUD) remain the gold standard for treating OUD, but treatment initiation and adherence remain challenging. Exclusive utilization of pharmacotherapy as a treatment modality for OUD is sub-optimal, and a combination of psychotherapies and pharmacotherapies is recommended. General trends indicate the benefits of peer mentoring and MBRP separately.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!